title: Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma.
abstract: Differences in stromal and epithelial cell staining for androgen and glucocorticoid receptors (ARs and GRs) were investigated in 20 patients with clinically localized prostatic carcinoma treated by radical prostatectomy. Sections of benign prostatic hyperplasia and prostatic carcinoma from each patient were stained with antibodies to AR and GR using an avidin-biotin peroxidase technique. The specificity of the GR immunoreactivity was established in benign prostatic hyperplasia and prostatic carcinoma by immunohistochemistry using the GR antibody absorbed with synthetic peptide and Western blotting. Nuclear staining intensity and percentage of nuclei stained were summed to obtain AR and GR immunostaining scores. AR staining of prostatic carcinoma epithelial [103 +/- 58 (SD)] and stromal (126 +/- 48) nuclei was less than in benign prostatic hyperplasia (142 +/- 47 and 169 +/- 56; paired Student's t tests, P = 0.02 and P = 0.01); however, no difference in staining intensity occurred between stroma and epithelium in either tissue type. GR stained intensely in stromal cells from benign prostatic hyperplasia (189 +/- 50) and prostatic carcinoma (163 +/- 60). However, prostatic carcinoma epithelial cells (34 +/- 57) had low levels of glucocorticoid receptor staining (P < 10(-7)), and benign prostatic hyperplasia epithelium (74 +/- 51) was intermediate. In most patients, GR could not be detected in nuclei of prostatic carcinoma epithelial cells but was undiminished in stromal cell nuclei. There was no relationship by multivariate regression analysis between AR or GR staining and age, serum prostate-specific antigen, Gleason grade, or pathological stage. In comparison with AR, the greater variability of GR staining in epithelium versus stroma of prostatic carcinoma warrants further study of GR, particularly in the area of stromal-epithelial interaction.
authors.affiliation: Departments of Surgery, University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill, 27599, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Mohler
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: K
authors.initials: K
authors.lastname: Hamil
authors.forename: S H
authors.initials: SH
authors.lastname: Hall
authors.forename: J A
authors.initials: JA
authors.lastname: Cidlowski
authors.forename: E M
authors.initials: EM
authors.lastname: Wilson
authors.forename: F S
authors.initials: FS
authors.lastname: French
authors.forename: M
authors.initials: M
authors.lastname: Sar
mesh_terms: D000368:Aged; D000616:Aminoglutethimide / Q000494:pharmacology; D004847:Epithelial Cells / Q000737:chemistry; D006801:Humans; D007150:Immunohistochemistry; D007654:Ketoconazole / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000737:chemistry*; D011944:Receptors, Androgen / Q000032:analysis*; D011965:Receptors, Glucocorticoid / Q000032:analysis*; D017154:Stromal Cells / Q000737:chemistry
chemical_list: D011944:Receptors, Androgen; D011965:Receptors, Glucocorticoid; D000616:Aminoglutethimide; D007654:Ketoconazole